[1] Perdomo CM, Cohen RV, Sumithran P, et al. Contemporary medical, device, and surgical therapies for obesity in adults[J]. Lancet. 2023,401:1116-1130. [2] Rong L, Zou J, Ran W, et al. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)[J]. Front Endocrinol. 2023,13:1087260.doi:10.3389/fendo.2022.1087260. [3] Zhang X, Ha S, Lau HC, et al. Excess body weight: novel insights into its roles in obesity comorbidities[J]. Semin Cancer Biol. 2023,92:16-27. [4] Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease:from pathophysiology to therapeutics[J]. Metabolism. 2019,92:82-97. [5] Tanase DM, Gosav EM, Costea CF, et al. The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD)[J]. J Diabetes Res. 2020,2020:3920196.doi:10.1155/2020/3920196. [6] Watt MJ, Miotto PM, De Nardo W, et al. The liver as an endocrine organ-linking NAFLD and insulin resistance[J]. Endocr Rev. 2019,40:1367-1393. [7] Berasain C, Arechederra M, Argemí J, et al.Loss of liver function in chronic liver disease: an identity crisis[J]. J Hepatol. 2023,78:401-414. [8] Guo X, Yin X, Liu Z, et al.Non-alcoholic fatty liver disease (NAFLD) pathogenesis and natural products for prevention and treatment[J].Int J Mol Sci.2022,23:15489. doi:10.3390/ijms232415489. [9] Pouwels S, Sakran N, Graham Y, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss[J]. BMC Endocr Disord. 2022,22:63. doi:10.1186/s12902-022-00980-1. [10] Lee ES, Kwon MH, Kim HM, et al. Curcumin analog CUR5-8 ameliorates nonalcoholic fatty liver disease in mice with high-fat diet-induced obesity[J]. Metabolism. 2020,103:154015. doi:10.1016/j.metabol.2019.154015. [11] Rinschen MM, Ivanisevic J, Giera M, et al. Identification of bioactive metabolites using activity metabolomics[J]. Nat Rev Mol Cell Biol. 2019,20:353-367. [12] Zhang XL,Chen L,Yang J,et al.Vitamin D alleviates non-alcoholic fatty liver disease via restoring gut microbiota and metabolism[J]. Front Microbiol. 2023,14:1117644. doi:10.3389/fmicb.2023.1117644. [13] Jia W, Wei M, Rajani C, et al. Targeting the alternative bile acid synthetic pathway for metabolic diseases[J]. Protein Cell. 2021,12:411-425. [14] Liu R, Chen L, Wang Z, et al. Omega-3 polyunsaturated fatty acids prevent obesity by improving tricarboxylic acid cycle homeostasis[J]. J Nutr Biochem. 2021,88:10850.doi:10.1016/j.jnutbio.2020.108503. |